Portal de Periódicos da CAPES

Placebo-controlled double-blind evaluation of trimethoprim-sulfamethoxazole treatment of Yersinia enterocolitica gastroenteritis

1984; Elsevier BV; Volume: 104; Issue: 2 Linguagem: Inglês

10.1016/s0022-3476(84)81020-3

1097-6833

C. H. Pai, Faye Gillis, Elaine Tuomanen, Melvin I. Marks,

Viral gastroenteritis research and epidemiology

YERSINIA ENTEROCOLITICA is an important cause of gastroenteritis, parcitularly in childrenJ 3 The illness is generally mild and seif-limiting, although diarrhea may persist for several weeks. Excretion of the organ!smin the stools continues for an average of 4 w~ks after cessation of symptoms, which may contribute to a i'e.lat!vely high incidence of intrafamilial spread; in a prospective siudy performed in Montreal, 29% of siblings and 6.8% of ffdult contacts became colonized with Y. enterocoI.itica, and one half of them developed symptoms, z Extragastrointestinal tract infections are not commo n , but septicemia and Other supi~urative infections have been reported, usually in patients with underl3,ing diseases? 9 Y. enterocolitica is susceptible in vitro to trimethoprimsulfamethoxazole find to aminoglycosides46; however, there are no controlled studies of the e .fficacy of antimicrobial therapy in gastroenteritis. We comPared TMP-SMZ with placebo for the treatment of Y. enterocoliiica gastroenteritis in infants and children.